Actinogen's Trial Validates Xanamem for Alzheimer's, Showcasing Consistent Effectiveness Actinogen Medical's Xanamem shows promising results in recent trials, maintaining therapeutic blood levels in both fed and fasted states, crucial for Alzheimer's treatment.

Actinogen's Trial Validates Xanamem for Alzheimer's, Showcasing Consistent Effectiveness #Australia #Sydney #Alzheimer's #Xanamem #Actinogen

Actinogen Medical's Innovative Alzheimer's Trial Now Recruiting Participants in the US Actinogen Medical's new trial invites individuals with Alzheimer's to explore a promising treatment that may slow cognitive decline, changing the therapeutic landscape.

Actinogen Medical's Innovative Alzheimer's Trial Now Recruiting Participants in the US #United_States #Various #Alzheimer's_Disease #Xanamem #Actinogen

Actinogen Reaches Recruitment Milestone in XanaMIA Alzheimer's Trial with Interim Analysis Set for 2026 Actinogen Medical has enrolled its 100th participant in the XanaMIA trial for Alzheimer's disease, with key interim analysis planned for January 2026.

Actinogen Reaches Recruitment Milestone in XanaMIA Alzheimer's Trial with Interim Analysis Set for 2026 #Australia #Sydney #Alzheimer's_Disease #Actinogen #XanaMIA

Actinogen boosts trial with Cambridge Cognition's digital suite - PharmaTimes Partnership aims to advance Alzheimer's research with innovative tools

#digitalneuroscience #brainhealth #Actinogen #ActinogenMedical #neuropsychiatricdiseases #CambridgeCognition #emestedastat #Xanamem #CANTABAttention #Alzheimersresearch #AlzheimersDisease #XanaMIAclinicaltrail #dementia #plasmabiomarker #biomarker #pTau181
pharmatimes.com/news/actinog...